Cardiovascular Clinical Studies

This channel includes news and new technology innovations from cardiovascular clinical trials. These clinical studies include all cardiac subspecialties.

Phase 2 trials underway with ninerafaxstat in three cardiovascular indications; multiple data read-outs expected in 2023

News | Cardiovascular Clinical Studies

Imbria Enrolls First Patient in the Phase 2 IMPROVE-DiCE Clinical Trial Evaluating Ninerafaxstat in Patients with Heart Failure with Preserved Ejection Fraction

January 11, 2023 — Imbria Pharmaceuticals, Inc., a clinical stage, cardiometabolic company developing novel therapies ...

January 11, 2023

$TGCV is an emerging cardiovascular disorder characterized by diffuse narrowing coronary atherosclerosis with triglyceride (TG) deposition caused by defective intracellular lipolysis. TGCV is an often-undiagnosed condition in patients who are resistant to standard therapies. Panels A and B concern two patients in their 60s with refractory angina pectoris and diabetes mellitus. After being diagnosed with TGCV, they started dietary intake of tricaprin. Their symptoms improved within a couple of months. Follow-$

News | Heart Failure

A Dietary Supplement Leads to Remarkable Regression in Atherosclerotic Lesions

January 9, 2023 — When we were little, our parents told us to take our vitamins so we could grow big and strong. Now ...

January 09, 2023

Acutus Medical, Inc., an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced the acceptance of the AcQForce Flutter abstract titled “AcQForce Flutter Trial Clinical Results: Force Sensing RF Ablation with Low Flow Gold Tip Catheter for Typical Flutter”

News | Cardiovascular Clinical Studies

Acutus Medical Announces Acceptance of the AcQForce Flutter Abstract for Presentation at the 2023 AF Symposium

January 3, 2023 — Acutus Medical, Inc., an arrhythmia management company focused on improving the way cardiac ...

January 03, 2023

The U.S. Food and Drug Administration (FDA) has approved the BioFreedom Drug Coated Coronary Stent (DCS) System – P190020 from Biosensors International.

News | Stents Drug Eluting

FDA Approves BioFreedom Drug Coated Coronary Stent (DCS) System – P190020

January 2, 2023 — The U.S. Food and Drug Administration (FDA) has approved the BioFreedom Drug Coated Coronary Stent (DC ...

January 02, 2023

News | Cardiovascular Clinical Studies

Cardiovascular Research Foundation Announces Clinical Trials Center Executive Director

December 30, 2022 — The Cardiovascular Research Foundation (CRF) recently announced that Alexandra Popma, MD, has joined ...

December 30, 2022

Protein could yield potential therapeutic strategy to detect and prevent cancer therapy-associated heart failure

News | Heart Failure

Researchers ID Protein that may Protect the Heart During Certain Cancer Treatment Regimens

December 29, 2022 — Anthracyclines are a class of chemotherapies effective in treating many forms of cancer, including ...

December 29, 2022

Impella ECP, the world's smallest heart pump, is placed percutaneously into the heart's left ventricle. (Graphic: Business Wire)

News | Cardiovascular Clinical Studies

FDA Approves Impella ECP Pivotal Heart Pump and First Patients Enrolled in Pivotal Clinical Trial

December 28 2022 — Abiomed announces the United States Food and Drug Administration (FDA) has approved the version of Im ...

December 28, 2022

Keyur Vora, MD, MS, George Revtyak, MD, and Rohan Dharmakumar, PhD with the first patient to enroll in a new cardiovascular clinical trial.

News | Cardiovascular Clinical Studies

First Patient Enrolls in IU-led Clinical Trial to Study Treatment for Acute Heart Attack Complications

December 27, 2022 — A groundbreaking new clinical trial to determine the effectiveness of a new treatment for patients ...

December 27, 2022

Individuals with coronary artery disease exist on a spectrum of disease, such as the amount of plaque build-up in the arteries of the heart; however, the disease is conventionally classified as broad categories of case (yes disease) or control (no disease), which may result in misdiagnosis. A digital marker for coronary artery disease derived from machine learning and electronic health records can better quantify where an individual falls on the disease spectrum. Credit: Icahn School of Medicine at Mount Si

News | Heart Failure

Digital Marker for Coronary Artery Disease Built by Researchers at Mount Sinai

December 22, 2022 — Using machine learning and clinical data from electronic health records, researchers at the Icahn ...

December 22, 2022

Bempedoic acid becomes the first ATP citrate lyase inhibitor and first oral non-statin to meet the major adverse cardiovascular events (MACE-4) primary endpoint

News | Cardiovascular Clinical Studies

CLEAR Outcomes Accepted as Late-Breaking Clinical Trial at ACC.23 Annual Scientific Session & Expo together with the World Congress of Cardiology

December 21, 2022 — Esperion announced that the landmark Cholesterol Lowering via Bempedoic acid, an ACL-Inhibiting Regi ...

December 21, 2022

Companies initiate research agreement supporting development of new AI-ECG algorithm to help identify patients who may be at risk of cardiac amyloidosis

News | Artificial Intelligence

Anumana and Pfizer Partner to Enable Early Detection of Underdiagnosed Cardiovascular Disease

December 19, 2022 — Anumana, Inc., an AI-driven health technology company and portfolio company of nference, has ...

December 19, 2022

Innovative approach can deliver high-fidelity cardiopulmonary exercise test results comparable to gold-standard testing with a wearable sensor during routine daily activities

News | Remote Monitoring

physIQ’s eVO2Max Demonstrates Breakout Ability to Estimate Cardiopulmonary Functional Capacity from Wearable Sensor Data During Daily Routine Activity

December 15, 2022 — physIQ announced a novel approach to estimating maximum oxygen utilization (VO2Max) using wearable ...

December 15, 2022

Doctors from the Emory Heart & Vascular Center are joining forces with the Family Heart Foundation, a leading research and advocacy organization, to find and more widely treat undiagnosed patients living with a common genetic condition that causes very high levels of unhealthy cholesterol, heightening the risk for heart attacks and strokes even at a young age.

News | STEMI

Emory Doctors and Family Heart Foundation Team Up to Help Patients with Dangerously High Cholesterol Caused by Genetic Condition

December 15, 2022 — Doctors from the Emory Heart & Vascular Center are joining forces with the Family Heart Foundation ...

December 15, 2022

From left, Qian Ma, PhD, and Yuqing Huo, MD, PhD. Photo courtesy of Michael Holahan, Augusta University

News | Heart Failure

New Target in the Fight Against Heart Disease

December 15, 2022 — Soon after cholesterol and fat start depositing on the lining of the blood vessels that supply your ...

December 15, 2022

Edwards Lifesciences identified the top data releases from 2022 that contributed most to shaping awareness about the extent and impact of underdiagnosis and undertreatment of aortic stenosis (AS).

News | Stroke

Preventing Millions of Strokes and Heart Attacks Doesn’t Have to Come with the Risk of Life-threatening Bleeding

December 14, 2022 — Verseon announced that the European Journal of Medicinal Chemistry has published a paper describing ...

December 14, 2022